Publication analysis · Module 3
Semaglutide and alcohol: an early randomized trial
A nine-week phase 2 trial randomized 48 adults with alcohol use disorder who were not seeking treatment to semaglutide or placebo. Laboratory alcohol consumption and some weekly drinking and craving measures improved. Average drinks per calendar day and the number of drinking days did not significantly change.
Original publication
Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial
DOI 10.1001/jamapsychiatry.2024.4789 · PMID 39937469 · Citation pending verification
Educational information for healthcare professionals and the general public. Not individual medical advice, diagnosis, treatment, or a recommendation to use a compound.
A nine-week phase 2 trial randomized 48 adults with alcohol use disorder who were not seeking treatment to semaglutide or placebo. Laboratory alcohol consumption and some weekly drinking and craving measures improved. Average drinks per calendar day and the number of drinking days did not significantly change.
Different drinking outcomes answer different questions. This small, short trial supports larger studies, not a claim of established treatment or long-term abstinence. Its selected population and laboratory outcome limit generalization.
References
Bibliographic sources shown for transparency. Citation verification pending; no citation is marked verified.
Related resources
Publication analysis · Module 3
SURMOUNT-1: interpreting a multigroup obesity trial
SURMOUNT-1 randomized 2,539 adults with overweight or obesity, excluding diabetes, to three weekly tirzepatide groups or placebo for 72 weeks. Mean weight changes were −15.0%, −19.5%, and −20.9% in the 5-, 10-, and 15-mg study groups, respectively, versus −3.1% with placebo. These amounts identify trial groups, not an administration recommendation.
Publication analysis · Module 3
STEP 9: weight, knee pain and function
STEP 9 randomized 407 adults with obesity and painful knee osteoarthritis to semaglutide or placebo for 68 weeks, with lifestyle counseling in both groups. Weight and WOMAC pain scores improved more with semaglutide; physical function also improved. Gastrointestinal problems were the most common reason for treatment discontinuation.
Publication analysis · Module 3
BELIEVE: body composition is not the same as function
BELIEVE was a randomized phase 2 trial in 507 adults with obesity, excluding diabetes. It compared bimagrumab, semaglutide, combinations and placebo over 48 weeks, followed by an open-label extension. Bimagrumab is an investigational monoclonal antibody, not a peptide agonist.